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Abstract
Glycine is one of the major inhibitory neurotransmitters in the central nervous system. It is
implicated in the regulation of motor-sensory function such as; pain perception, reflex responses, and is
essential for early development of the CNS. In addition to its inhibitory actions, it acts as an obligatory
co-agonist for the activation of glutamatergic NMDARs, which are of pivotal importance in the process
of learning and memory, its dysfunction leads to several neurodegenerative diseases. Two high affinity
Na+/Cl- dependent transporters GlyT1 and GlyT2 tightly regulate the availability of glycine present at
the synapse for the activation of NMDARs and GlyRs. GlyT1 is ubiquitously expressed throughout the
brain, and is the only GlyT that is present at both glycinergic and glutamatergic synapses. The ability of
this protein in the regulation of inhibitory and excitatory synapses has increased the interest on the study
of mechanisms that might regulate this transporter, and could be potential targets for treating seve ral
neurological disorders. The overall goal of this present work was to investigate the regulation
mechanism of GlyT1, exerted by PKC-dependent ubiquitination. We have identified that PKC activation
leads to ubiquitination and internalization of GlyT1. The dependency of this effect on PKC-activation
was demonstrated by the prevention of ubiquitination and internalization of GlyT1 with the incubation
of BIM, a specific PKC-inhibitor prior to PMA stimulation. O nce internalized, the transporter can
follow two pathways - recycling and degradation - since co-localization with both Rab11 and Rab7
markers for recycling and late endosomes was observed. By using site-directed mutagenesis we
observed that ubiquitination can modify any available lysine residue present at either the N- or Cterminals of GlyT1, and this post-translational modification is essential for the internalization of the
transporter. We also showed that preventing GlyT1 ubiquitination does not inhibit phosphorylation of
the transporter, but it does reverse the down-regulation in glycine uptake caused by PKC activation,
which was previously attributed to PKC-phosphorylation. Our study also comprises the identification of
PKC α isoform as responsible for the ubiquitination and internalization of GlyT1. Using specific isoform
vi

inhibitors for PKC and short interference RNA we identified PKC α as the PKC isoform regulating both
ubiquitination and internalization of the transporter. We also aimed to identify the E3- ligase that
mediated ubiquitination of GlyT1 in response to PKC activation, based on previous evidence that
suggests other transporters such as CAT-1, DAT and EAAT1 ubiquitination is mediated by Nedd4-1 and
Nedd4-2, respectively. We performed short interference RNA experiments of these two ligases on PAE
cells expressing GlyT1. However, siRNA of Nedd4-1, Nedd4-2, or both did not show any inhibitory
effect on the ubiquitination and internalization of GlyT1. This study provides new perspectives for the
molecular mechanisms regulating GlyT1.
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Chapter 1: Introduction.
1.1 Glycine Transporter 1 (GlyT1).
The gamma (γ) -aminobutyric acid (GABA) and glycine are the major inhibitory
neurotransmitters in the CNS. They control the function of all motor-neuron synapses, are
essential for appropriate spinal cord reflexes and coordinate the respiratory system. Both
neurotransmitters also play a pivotal role in the maturation of the CNS. In fetal development and
early post-natal life they have a major role as excitatory neurotransmission due to the absence of
the Cl-/K + antiporter system [1]. As the nervous system matures, GABA and glycine become
inhibitory. At those stages, improper function of any of these two systems have shown to be
lethal, promoting severe motor deficits and breathing inability [2]. The transport of
neurotransmitters is of fundamental importance for mainta ining proper signaling between
neurons [3, 4]. Intercellular communication in the central nervous system requires precise control
of the duration and the intensity of neurotransmitter action at specific molecular targets. After
they have been released at the synapse, neurotransmitters bind and activate pre- and/or
postsynaptic receptors [5]. In nervous systems of vertebrates, termination of synaptic
transmission is carried out by either enzymatic degradation of the neurotransmitters or by
actively transport back into the pre- synaptic neuron and/or glial cells by neurotransmitter
transporters, thus preventing spillovers and limiting synaptic cross-talking [6-9].
Neurotransmitter transporters can be classified in super- families, families, and
subfamilies according to their primary structures and site of action. In particular, the latter
criterion allows the distinction of two super-families: namely, the plasma membrane transporters
and the vesicular membrane transporters. The super- family of plasma membrane transporters can
be further divided into two families depending on their ionic dependence: 1) the Na +/Cl2
1
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dependent transporters and 2) the Na+/ K +-dependent transporters [5]. Plasma membrane
neurotransmitter transporters, as the name suggests, are localized exclusively at the plasma
membrane and are responsible for the high-affinity uptake of neurotransmitters by neurons and
glial cells; DAT, SERT, NET, GAT1-4 and GlyTs neurotransmitters transporters belong to the
SLC6 gene family transporters (Table 1) and their transport is coupled to the symport of Na+/Cl[4]. The important role that these transporters play in neurotransmission is highlighted by their
involvement in several neurological and psychiatric diseases [4]. Research on neurotransmitter
regulatory pathways has increased over the last decade and has established them as potential and
promising novel therapeutic drug targets [4].

*Table 1 shows the endogenous substrates and disease relation of the members of the solute
carrier 6 family of transporters. [4, 10, 11]
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It has been suggested that extracellular glycine concentration is tightly regulated by
glycine transporters (GlyTs) [12]. There are two high-affinity transporters for glycine termed
GlyT1 and GlyT2, and they seem to have complimentary functions in neurotransmission [13].
GlyT1 has a 2Na+/1Cl-/Gly stoichiometry, which facilitates bi-directional transport and creates
the proper conditions for the regulation of glycine in the extracellular space. GlyT2
stoichiometry is 3Na+ /1Cl-/Gly making it more complicated for reverse transport of glycine, thus
GlyT2 plays an essential role in maintaining a high intracellular glycine concentration [6]. GlyT1
and GlyT2 are polytopic transmembrane proteins, which according to secondary structure
predictions have 12 trans- membrane domains and intracellular carboxyl and amino termini
(Fig.1). Both GlyTs exist in different isoforms: three GlyT2a, b, and c, which differ in their
amino terminal, and five GlyT1 isoforms; a, b, and c differing in their amino terminal and
different carboxyl terminals d and e. It has been suggested that GlyT1 isoforms might be
different in tissue-specific expression and their genetic expression is regulated by different
promoter usage, but their affinity to glycine is similar [6, 14]. Both transporters are glycosylated
at four Asparagine (Asn) residues located in the second large extracellular loop, which triggers
and targets the transporter to its cellular location, the plasma membrane. Similar to most
members of the SCL6 family, its amino acid structure contains multiple consensus sites for
phosphorylation [13, 15]. Immunohistochemistry has shown that GlyT1 is distributed throughout
the brain and specifically in regions shown to express NMDARs including the spinal cord, brain
stem, cerebellum, hippocampus, and cortex [7]
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Biochemical experiments have revealed that GlyT1 forms complexes with NMDA
receptors, most likely maintained by common anchoring of both GlyT1 and NMDARs to the
scaffolding protein PSD-95. These studies indicate that neuronal GlyT1 has optimal distribution
to regulate the binding of glycine to NMDA receptors. Reduced expression of GlyT1, or its
pharmacological inhibition, increases the extracellular glycine concentration and potentiates
NMDAR responses [8, 16-18]. NMDA receptors are abundant, ubiquitously distributed
throughout the brain and are critical to excitatory neurotransmission and normal CNS function
[19, 20]. The importance of GlyT1 has been well demonstrated as a modulator of glutamatergic
NMDARs and its relevance in regulating proper glycinergic neurotransmission; the second being
of fundamental importance for early post-natal survival, proper motor-sensory function, and
rhythmic breathing [16]. The putative role of GlyT1 in regulating glycine availability at NMDA,
promoting enhanced memory retention and protection against some amphetamine induced effects
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has increased the interest in developing high-affinity inhibitors to this transporter as a novel class
of cognitive enhancer and antipsychotic treatments [13, 16].

1.2 Protein Kinase C and ubiquitination.
The Protein Kinase C (PKC) family of enzymes consists of eleven isofo rms of serinethreonine kinases. These enzymes play important roles in the regulation of cell growth,
differentiation, apoptosis, secretion, neurotransmission and signal transduction [21-23]. The PKC
family is divided into three subfamilies based on sequence and activator requirements (Fig.2).
Conventional PKCs require calcium, diacylglycerol (DAG), and an anio nic phospholipid for
activation. This family includes PKC alpha (α), beta (β), and gamma (γ), each of which contains
two- cysteine rich domains, a phospholipid-binding and DAG/phorbol ester binding C1 domain,
and a calcium-C2 binding domain. Novel PKCs require DAG but not calcium. They are
characterized by having a functional C1 domain and lacking a functional C2 domain. This family
includes PKC delta (δ), epsilon (ε), eta (η), nu (ν), and theta (θ). The last subfamily is known as
atypical PKCs, which contain a partial/truncated C1 domain unable to bind DAG or phorbol
esters and thus require neither calcium nor DAG for activation. This family comprises PKC iota
(ι), lamda (λ), and zeta (ζ) [21-23].

5

PKC regulates numerous cellular functions. Multiple studies have defined roles for PKC
in the regulation of receptor desensitization and internalization. Emerging recent evidence points
to more general roles of PKC in regulating the processes of endocytosis and trafficking of
neurotransmitter transporters [21, 22, 24]. In vivo activation of PKC requires the action of
hormones, neurotransmitters, and growth factors, which can stimulate phospholipase Cdependent hydrolysis of phosphatidylinositol 4,5 bisphosphate, generating two by-products:
ionositol 1,4,5-triphosphate that acts as a messenger to mobilize Ca + from intracellular
compartents, and diacylglycerol (DAG) [25]. Diacylglycerol and Ca+ are the physiological
activators of PKC, but it has been shown that phorbol esters can mimic the actions of DAG due
to a structural and chemical resemblance (Fig.3). They bind to the activation site of PKC and
6

stimulate its kinase activity (Fig.2) [26]. Interestingly, it has been suggested that upon PKC
activation the protein promotes its own ubiquitination and degradation by the ubiquitinproteosomal pathway, following a negative feedback control mechanism [26]. Recently, analyses
of amino acid sequences in glycine transporters have identified the consensus sites of
phosphorylation for several protein kinases such as PKC and Protein Kinase A [27-29].
Furthermore, it has been previously suggested that the activation of PKC by 4α-phorbol 12myristate 13-acetate (PMA) induces a decrease in the uptake o f glycine, via inhibition of GlyT1
[28, 30].

Ubiquitination is a post-translational modification that mediates the covalent conjugation
of ubiquitin to protein substrates. Ubiquitin protein consists of 76 highly conserved amino acids,
containing a di-glycine motif at its C-terminal in which the last residue (glycine 76) can be
conjugated to the ε amino group of a lysine residue in a target protein [31, 32]. It was originally
believed that the role of ubiquitination was targeting proteins to the 26S proteasome for
7

degradation, but newly obtained evidence ind icates that ubiquitination can be involved in many
other processes, such as membrane trafficking, DNA repair, and transcription [31, 33]. The
mechanism of ubiquitination involves the sequential action of three enzymes: E1-ubiquitin
activating enzyme which is ATP-dependent, E2-ubiquitin conjugating enzyme, and E3-ubiquitin
ligase enzyme, which provides specificity for target recognition [31, 32]. Target proteins can
become mono-ubiquitinated, multi- monoubiquitinated, or poly- ubiquitinated (forming ubiquitin
chains), since the ubiquitin protein contains seven lysine residues capable of conjugating
ubiquitin and forming chains. Lys
been suggested that Lys
63-

48-

48-

and Lys

63-

linked chains are the most abundant and it has

chains serve as the recognition signal for the proteasome, while Lys

chains and mono-ubiquitination play an important role in endocytic trafficking, protein

translation, and DNA repair (Fig.4) [33]. The importance of the ubiquitin proteasome system and
a tight relation between ubiquitination and de-ubiquitination of essential proteins in the central
nervous system has been highlighted in recent years. Numerous evidence supports the vital
function of ubiquitin for the development, maintenance and remodeling of synapses [34, 35].
Ubiquitin modification has been associated with protein turnover in the brain, but recent findings
support the role of ubiquitin as a dynamic regulator of pre-synaptic proteins activity, such as
neurotransmitter transporters and numerous receptors including inhibitory Glycine and GABA
receptors and excitatory NMDA and AMPA receptors. All these together suggest that this posttranslational modification acts as a modulator of synaptic transmission [34, 36-38].
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1.3 NMDA receptor and Disease.
Three classes of glutamate- ion channels have been identified as transducers of the
excitatory

postsynaptic

signal.

These

are:

AMPA

(α-amino-3-hydroxy-5-methyl-4-

isoxazolepropionic acid), Kainate and NMDA (N-methyl D-aspartate) receptors. NMDA
receptors are abundantly expressed throughout the brain in approximately 70% of adult
excitatory synapses [39]. The activation of NMDAR depends on the binding of a
neurotransmitter (glutamate), and a modulator (glycine), which is present in the extracellular
space at more constant levels (Fig. 5). Binding of glutamate and glycine promotes channel
opening, allowing the entrance of Ca2+ and finally leading to de-polarization of the postsynaptic
neuron [19, 40]. NMDARs are critically implicated in neuronal development, synaptic plasticity,
excitoxicity, learning and memory processes [20, 39, 41-43]. As it was previously mentioned,
GlyT1 is ubiquitously distributed in the brain, but it has shown specific expression in areas
9

where NMDARs are present. In vivo and in
vitro studies have demonstrated that the
actions of specific GlyT1 inhibitors (GTIs)
augment NMDARs- mediated transmission
in the hippocampus and the prefrontal
cortex [12, 42, 43]. NMDARs act by
linking

neurotransmission

with

the

electrical state of the neuron. Its sustained
activation promotes

signaling

nucleus

induces

which

to

the

CREB

phosphorylation, multiple gene activation,
and long-term synaptic plasticity. The role of NMDARs in synaptic plasticity, which is the
mechanism underlying learning and memory, has increased the interest of research groups
involved in drug discoveries to treat cognitive dysfunctions [19, 39].
NMDARs are heterotetramers composed by a combination of NR1 and NR2 subunits,
glutamate binding site is located at the NR1 subunit, and co-activator glycine binds to NR2
subunit [44]. The occupation of the glycine-binding site is a pre-requisite for NMDAR activation
by glutamate and it has been reported that glycine concentration in the vicinity of NMDARs is
controlled by GlyT1, which expression includes astrocytes and gluatmatergic pre- and postsynaptic neuronal terminals [45, 46]. The glycine uptake process dependent on GlyT1 is so
efficient that NMDARs glycine-binding site never appears to be saturated at synap ses located at
the prefrontal cortex and hippocampus [45]. GlyT1(+/-) heterozygote mice models have
demonstrated that a reduction of GlyT1 expression enhances NMDARs function; a reduction of
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50% in the expression of GlyT1 promoted NMDARs and AMPARs excitatory post-synaptic
currents to increase by 36%, without altering the concentration of the receptors [46]. Mice
models with reduced Glyt1 expression performed better on several memory and spatial learning
tests, showed greater resistance to amphetamine induced pre-pulse inhibition, and a robust and
clear latent inhibition compared to the wild type mice [16, 46, 47].
The role of NMDARs in the processes of learning and memory and its implications with
numerous neurological diseases has increased the interest on finding molecular targets that might
aid in the modulation of these receptors [48]. One of the main approaches to potentiate
NMDARs neurotransmission has been focused on trying to increase the extracellular levels of
glycine by blocking glycine re-uptake through GlyT1 [17-19]. Direct activation of the receptor
by glutamate is not an option because of obvious concerns about excitotoxicity. This generates
neurotoxic cascades due to an over-activation of glutamate receptors resulting in a massive
influx of extracellular calcium and liberation of intracellular calcium from the endoplasmic
reticulum, leading to neuronal death [49]. Potentiating the activity of NMDARs can be beneficial
for improving learning and memory tasks and could also be therapeutic for the treatment of
diseases such as Alzheimer’s, obsessive compulsive disorder (OCD) and schizophrenia [44, 50].
The involvement of GlyT1 in the regulation of NMDARs neurotransmission highlights the
transporter as an important drug target for the treatment of neurological disorders in which
NMDARs are involved [18].

11

1.4 Role of GlyT1 as pharmacological target in schizophrenia.
Schizophrenia affects 1% of the population worldwide, its effects range from a cognitive
dysfunction to social withdrawal and is considered one of the most disabling diseases [41]. For
several years, the study of schizophrenia has been mainly focused on the dopaminergic
hypothesis of schizophrenia, which proposes that certain dopaminergic pathways are overactive
in schizophrenia patients. Conventional dopamine receptor-blocking antipsychotics are effective
for positive symptoms, but they have limited effects on negative and cognitive symptoms,
suggesting that these symptoms possibly involve other neurotransmitter systems besides
dopamine [17, 51]. Recently, several lines of investigation have implicated glutamatergic
dysfunction in the pathophysiology of schizophrenia. The glutamatergic hypothesis of
schizophrenia originated from the observation that NMDARs blockade with phencyclidine (PCP)
or ketamine produced psychosis and cognitive deficits in normal subjects that resembled the
symptoms of schizophrenic patients [19, 40, 41]. Mouse models in which NMDARs have been
blocked showed hyperlocomotion and characteristic stereotypic behaviors that can be compared
to positive symptoms of schizophrenia; similarly isolation and reduced sexual interactions that
resemble negative symptoms were characteristic on these animal models (Shim 2007). It has
been observed that enhancing the function of NMDARs improves negative and cognitive
symptoms in some patients with schizophrenia[19, 41]. Recent evidence has also pointed out that
NMDA-Rs are localized in brain circuits that have a role in dopaminergic neurotransmission
regulation, suggesting that the deficits observed in schizophrenia patients on the dopamine
system might be a consequence of an irregularity of NMDARs function [41] . The hypothesis
that increasing NMDARs function might alleviate schizophrenic- like symptoms has increased
the interest of research groups and pharmacological companies in developing agents that can
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potentiate NMDARs. One of the first approaches consisted in saturating the receptor glycinebinding site with high doses of glycine and/or D-serine, although animal models have shown
improvements, there are several disadvantages to this approach; such as very high concentration
of glycine are needed because of the poor capability this aminoacid shows on crossing the blood
brain barrier. D-serine also represents a challenging treatment, since it is very efficiently
metabolized by D- aminoacid oxidase and high doses of D-serine have been associated with
nephrotoxicity [50, 52]. It was then proposed that targeting the mechanisms that regulate glycine
levels might account for a more efficient treatment in enhancing NMDARs function [50]. The
co-localization of GlyT1 with NMDARs and evidence that indicates that there are no
irregularities with the expression of GlyT1 in schizophrenia has postulated GlyT1 inhibitors as
promising candidates for the treatment of this disorder. Starting in the mid-1990s, several groups
have been focusing on developing high-affinity inhibitors. One of the most widely known is
Sarcosine; that on a double-blind study showed to be more efficient in every aspect than Dserine. Patients with schizophrenia experienced improvement in positive and negative symptoms
and cognitive functions when treated with 2g/day of Sarcosine [53]. Many other high-affinity
GlyT1 inhibitors have been developed employing Sarcosine as a background, such as Org24461,
Org 25935, RG1678, NFP/ALX-5407. All of these have shown to be effective in enhancing
NMDA function and proved efficacy in the treatment of other disorders such as OCD and
alcohol abuse. They have even been suggested as possible treatment for Parkinson’s disease[50,
52, 54]. The major disadvantage among the current GlyT1 inhibitors is that they have shown to
be toxic or associated with cancer predisposition, and most of them have been discarded during
the late stages of clinical trials [50]. It is believed that a deeper understanding on the regulatory
mechanisms of GlyT1 can lead to the development of better agents that could be employed in the
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treatment of schizophrenia and other neurological disorders with which the transporter is
associated.

1.4 Dissertation Aims
Previous studies have shown that post-translational modifications such as ubiquitination
and phosphorylation play an important role in the regulation of neurotransmitter transporters.
The dopamine transporter (DAT), another member of the SLC6 family that s hares a similar
topology with GlyTs, was demonstrated to be ubiquitinated and internalized as a consequence of
Protein Kinase C (PKC) activation by treatment with 4α-phorbol 12- myristate 13-acetate (PMA)
[55]. Given that regulation and functioning of GlyT1 has been poorly studied, the main
goal this dissertation is to dissect the specific role that ubiquitination plays in the regulation
of GlyT1. The working hypothesis of this project is that GlyT1 is ubiquitinated in a PKCdependent manner, which in turn is necessary for its internalization. This study will also focus on
identifying the specific sites on GlyT1 that are modified by ubiquitin, the endocytic pathway
followed by the ubiquitinated GlyT1, and identifying the specific PKC isoform implicated in
ubiquitination of GlyT1. The goal throughout this investigation is to gain further knowledge on
the regulatory pathway of GlyT1, which can serve as an important step towards future drug
development for alleviating neurological disorders, such as Schizophrenia, OCD, in which
GlyT1 can be used as a cognitive enhancer. The specific aims to be investigated in this
dissertation are the following:
Aim 1: Study the role of PKC-dependent ubiquitination on endocytosis of GlyT1b and
GlyT1c. Several groups have described the role of ubiquitination in the regulation of several
plasma membrane transporters, such as the dopamine transporter [56] and the glutamate
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transporter [57], among many others. It has been observed that activation of PKC rapidly
decreases the quantity of these transporters present at the plasma membrane, and ubiquitination
has been proposed to mediate this process. Based on the previous findings establishing the role
of ubiquitination in the endocytosis of several membrane transporters, we intend to make use of
Porcine aortic endothelial (PAE) cells as our expression model, to investigate the following:
i)

Determine if GlyT1a, GlyT1b and GlyT1c are ubiquitinated in response to PKC
activation.

ii)

Determine if PKC-dependent ubiquitination promotes the internalization of GlyT1b
and c.

iii)

Study the endocytic pathway of the ubiquitinated and internalized GlyT1b and c.

Aim 2: Determine the location of ubiquitination sites on the Glycine Transporter 1 and
assess its importance on the regulation of the transporte r. Ubiquitin is known to modify
lysine residues of target proteins [31]. Previous studies involving mutagenesis of lysine residues
of several plasma membrane transporters have established the location at which this posttranslational modification takes place. It has been observed that a cluster of lysine residues
present at the C-terminal of the glutamate transporter is essential for its ubiquitination and
internalization [58]. By contrast, for the dopamine transporter, ubiquitination at any of three
lysine residues present at the N-terminal is essential for the internalization of this transporter. To
map the location of GlyT1 ubiquitination, we propose to perform the following:
i) Mutagenesis of lysine residues present at the intracellular amino and carboxyl-terminal of
GlyT1 b and c; to determine whether mutations of these lysine residues affect the
ubiquitination of GlyT1.
ii) Investigate if abolishment of ubiquitination prevents internalization of the transporter.
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iii) Determine whether multi- lysine mutants affect phosphorylation and down-regulation of
glycine uptake.
Aim 3: Determine the PKC isoform involved in ubiquitination and internalization of GlyT1
in PAE-C, and investigate if GlyT1 ubiquitination is dependent on Nedd4-1 or Nedd4-2 E3
ligases. GlyT1 activity has been described to be regulated by Protein Kinase C (PKC) [59].
Activation of PKC triggers transporter endocytosis, and a reduction in transport capacity
accompanied by posttranslational modifications such as ubiquitinatio n and phosphorylation. The
Protein Kinase C (PKC) family of enzymes consists of eleven isoforms that are sub-divided in
three families based on activator requirements. Due to the dependency of this modification on
PMA our primary targets will be conventional and novel PKCs [21-23]. It has been previously
observed that more than one PKC isoform can orchestrate different regulatory mecha nisms on a
target protein [60]. Our group previously described the dependency of GlyT1 phosphorylation on
PKCβ and the fact that the down-regulation of glycine uptake was dependent on the effects of
both PKCα and β.
PKC-dependent ubiquitination of the glycine transporter 1 is well demonstrated by data
presented on this dissertation, but the question arises on which intermediate is employed by PKC
to target ubiquitin to GlyT1. Previous studies have shown that activation of distinct kinases
might induce a switch in the activity of the Nedd4 family of E3- ligases by phosphorylating them
[61, 62]. It has also been demonstrated that PKC-dependent ubiquitination of the dopamine
transporter (DAT) requires the presence of Nedd4-2 [63], and that PKC-dependent ubiquitination
of the cationic aminoacid transporter (CAT-1) is dependent on Nedd4-1 [64]. The main goal of
this aim is to characterize the specific PKC isoform involved in ubiquitination and internalization
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of GlyT1 and identify the E3 ligase mediating GlyT1 ubiquitination for which the following will
be investigated:
i)

Utilizing inhibitors and siRNAs specific for the different PKC isoenzymes we
intend to investigate the specific PKC isoform mediating GlyT1 ubiquitination
and internalization.

ii)

Silencing of Nedd4-1 and Nedd4-2 to investigate if these E3 ligases are
involved on GlyT1 ubiquitination.

This investigation intends to provide further knowledge into the mechanism that regulates
the concentration and activity of GlyT1 at the plasma membrane via PKC-dependent
ubiquitination. Understanding how GlyT1 is regulated by post-translational modifications such
as ubiquitination, might lead to alternative approaches to target this important modulator of
neurotransmission.
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Chapter 2: Ubiquitination and Internalization of the Glycine transporter 1 (GlyT1) by
Protein Kinase C (PKC).
PKC regulates numerous cellular functions, its activation leads to a signaling cascade
which may promote post-translational modifications of the target proteins, such as direct
phosphorylation and indirect ubiquitination [21]. It has been observed that plasma membrane
concentration of several neurotransmitters transporters becomes affected by the activation of
PKC. It was proposed that PKC-mediated phosphorylation is directly related to the trafficking of
the SCL6 family members [23, 56, 65-71]. Ubiquitination of cell surface proteins is a common
mechanism mediating internalization, endosomal sorting, recycling, proteosomal or lysosomal
degradation [57]. Ubiquitination plays a pivotal role in the endocytic trafficking of numerous
transporters and ion channels, and is widely recognized as a marker for clathrin scaffold adapters
[72]. Given the critical role of PKC on the regulation of transporters, previous studies in which
predicted phosphorylation sites were removed from neurotransmitter transporters (GLT-1 and
DAT) it was observed that these mutations, although they prevented phosphorylation, did not
affect the internalization of the transporter, suggesting that phosphorylation is not essential for
DAT or GLT-1 endocytosis [67, 73-76]. Recent evidence comprising neurotransmitter
transporters DAT, GLT-1, and GlyT2 revealed that activation of PKC promotes ubiquitination
and internalization of these transporters [56, 75, 77-79]. The objective of this aim is to determine
if PKC-activation by PMA, which mimics the action of DAG (a natural PKC-activator),
promotes ubiquitination of GlyT1a, GlyT1b and GlyT1c, stably expressed in PAE-cells. PAEcells will be used as our study model, since there is no endogenous expression of GlyT1 and
purification of the protein will be more effective by transfecting PAE-cells with a FLAG and 10
Histidines attached to the N- terminal of GlyT1 construct. To achieve this objective we tested the
working hypothesis that GlyT1 a, b, and c are ubiquitinated in a PKC-dependent fashion, and
that ubiquitination promotes GlyT1 internalization in PAE cells. We tested our working
hypothesis by using a combination of two different approaches: immunobloting to determine if
GlyT1 protein is ubiquitinated in response of PKC-activation, immunofluoresence assays to
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study the role of PKC-dependent ubiquitination on the internalization of GlyT1, as well as to
visualize the endocytic pathway followed by the internalized transporter (Fig.6).

2.1 Materials and Methods.

2.1.1 Chemicals and antibodies

PMA, N-ethylmaleimide, aprotinin and leupeptine were purchased from Sigma (St.
Louis, MO). Rabbit polyclonal antibodies to GlyT1 were kindly donated by Drs. Detlev Boison
and Dietmar Benke (University of Zurich). Monoclonal mouse to ubiquitin antibody was from
Santa Cruz Biotechnology (Santa Cruz, CA).
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2.1.2 Plasmid constructs and stable expression of human GlyT1 in PAE cells.

The cDNA encoding for the mouse glycine transporter (mGlyT1) was purchased from the
American Type Culture Collection (ATCC) and tagged with either YFP or Flag and 10X-His
epitope at the N-termini and the resulting constructs were cloned into pCDNA 3.1 (FH-GlyT1)
as previously described [56, 80]. Porcine aortic endothelial (PAE) cells were grown in F12
medium containing 10% fetal bovine serum and antibiotics. Cells were grown to 50–80%
confluence and transfected with the mammalian expression vector pcDNA 3.1-Flag His-GlyT1B
and Flag His-GlyT1C .Stable clonal cell lines were obtained and monitored by immunostaining
[31]. PAE-C stably expressing FH-GlyT1B and FH-GlyT1c were transfected with CFP-Rab7 and
YFP-Rab11 plasmids, which are markers of late and recycling endosomes respectively tagged
with Cyanin fluorescent protein and yellow fluorescent protein for purposes of microscopy
detection.

2.1.3 Gel electrophoreseis and western blotting.

Cells expressing FH-GlyT1b or FH-GlyT1c proteins were grown in 35- mm dishes and
treated with DMSO (1µM) for 60 min. at 37˚C, PMA (1 µM) for 15, 30, 60, 120 min. at 37˚C,
and BIM/PMA (1µM) 90 min at 37˚C. Cells were washed with cold PBS three times and
solubilized at 4 °C in lysis buffer, containing 25mM HEPES, 100mM NaCl, 15mM Immidazole,
10% Glycerol, 1% Triton, pH 8.0, and Protease Inhibitors cocktail. The lysates were cleared by
centrifugation for 10 min at 16,000 X g, and the FH-GlyT1 precipitated with 40 μl of Ni-NTA,
followed by five washes with wash buffer containing 25mM HEPES, 100mM NaCl, 15mM
Immidazole, 10% Glycerol, 1% Triton, pH 7.2, the protein was then eluted using 300mM
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immidazole in lysis buffer, and denatured by heating the beads in sample buffer at 95 °C for 5
min. The samples were subjected to SDS-PAGE (8% acrylamide) and transferred to
nitrocellulose membrane. Western blotting was performed with mouse and rabbit monoclonal
antibodies to ubiquitin or GlyT1, respectively, followed by secondary antibodies conjugated with
horseradish peroxidase. Detection of ubiquitination bands was accomplished using enhanced
chemiluminescence.

2.1.4 Immunofluorescence and microscopy.

Cells expressing FH-GlyT1b and FH-GlyT1c proteins were grown on glass coverslips
and treated with DMSO (1µM) for 60 min. at 37˚C, PMA (1µM) for 30, and 60 min. at 37˚C.
After treatment, the cells were washed with BSA-PBS, fixed with freshly prepared 4%
paraformaldehyde for 15 min at room temperature and mildly permeabilized using a 3- min
incubation in BSA-PBS containing 0.1% Triton X-100 and 0.5% BSA at room temperature. The
cells were then incubated at room temperature for 1 h with primary antibodies (1:500) diluted in
BSA-PBS and subsequently incubated for 1 h with secondary antibodies labeled with CY3 or
Alexa 488 (Jackson ImmunoResearch Laboratories). Both primary and secondary antibody
solutions were pre- cleared by centrifugation at 100,000 X g for 20 min. After staining, the
coverslips were mounted in Mowiol (Calbiochem). Results were monitored through fluorescent
microscopy.

21

2.2 Results

2.2.1 GlyT1 becomes ubiquitinated in response to PKC activation.
The relation between PKC-dependent ubiquitination and regulation of different
neurotransmitter transporters has been previously addressed in multiple studies [64, 75, 80]. In
the present investigation, PKC-dependent ubiquitination of GlyT1 is demonstrated using PAE
cells stably expressing FH-GlyT1a, FH-GlyT1b and FH-GlyT1c as our primary model of study.
Treatment of FH-GlyT1 PAE-cells with PMA, an activator of conventional and novel PKCs
triggered ubiquitination of the transporter with maximum ubiquitination between 30-60 minutes
(Fig.7a, b and c, lanes 4 and 5). The PKC dependency of this modification is demonstrated, since
treatment of the cells with bisindolymaleimide (BIM), a specific PKC inhibitor, prior to
treatment with PMA abolishes ubiquitination (Fig.7a, b and c, lane 2). These results suggest that
GlyT1 regulation by PKC is comparable to the regulation of other transporters exerted by this
kinase, and that ubiqutination of these membrane proteins might have diverse effects on its
expression at the plasma membrane and its function.
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2.2.2 Ubiquitinated GlyT1 is internalized and co-localizes with recycling and late
endosomes.
It has been proposed that activation of PKC results in the acceleration of GlyT1
internalization and the reduction of recycling of GlyT1, both leading to redistribution of GlyT1
from the plasma membrane to endosomes [81]. Our data shows that GlyT1 protein is
constitutively ubiquitinated at the plasma membrane as a consequence of PKC activation and this
results in internalization of the transporter. The transporter that is majorly found at the plasma
membrane under incubation with vehicle (DMSO), after 30-60 min incubation with PKCactivating agent (PMA) is clearly redistributed to intracellular compartments, which is shown by
co-localization of GlyT1 with early endosomes (EEA1) (Fig.8). The PKC-dependency of this
redistribution of GlyT1 is demonstrated by inhibiting PKC with BIM 30 min prior to PMA
incubation, which prevents internalization of the transporter. It has been observed that PKCdependent internalization of DAT results in reduced recycling and targeting to lysosomal
degradation [55]. Therefore, our goal was to determine the endocytic pathway followed by the
internalized GlyT1 after PKC activation. It has been stated that about 90% of receptors that are
internalized are recycled back to the plasma membrane, this traffic occurs through recycling
endosomes [82]. Rab proteins constitute the largest family of small GTPases, they’re activated
upon the binding of an effector (Ex. EEA1 acts as an effector of Rab 5 in the early endocytic
pathway), this transduces the signal of the Rab GTPase into a transport mechanism [82]. As
shown (Fig.9), PKC-dependent internalization of GlyT1b shows co- localization of both isoforms
with recycling (Rab 11) and late endosomes (Rab 7), suggesting that once the transporter is
ubiquitinated and internalized it can follow these two pathways; one that will recycle it back to
the plasma membrane and the second that finalizes in lysosomal degradation. It should be noted
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that the efficiency of the transfection with YFP-Rab11 and CFP-Rab 7 plasmids was very low.
Thus, only a few cells expressing both FH-GlyT1b and YFP-Rab11 or CFP-Rab7 were found in
each transfection experiment. By performing a quantification of the number of Rab-11 and Rab-7
endosomes co-localizing with GlyT1, respectively, we could state that approximately 90% of the
visible Rab-11 recycling endosomes co- localize with GlyT1; in contrast only 40% of Rab-7 late
endosomes show co-localization with the transporter. Similar results were obtained for FHGlyT1c (Appendix Fig.1). The exact mechanism by which the transporter is sorted into either the
degradation or the recycling pathway is unknown, but it has been previously suggested that deubiquitinating enzymes, may be responsible for the sorting of cargo proteins back to the plasma
membrane [35, 82].
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2.3 Discussion.
The role of protein kinases in the regulation of several membrane proteins, such as
receptors and transporters has been well documented [56, 65, 75, 83]. A special interest has
emerged from observations that show Protein Kinase C implications in regulating

several

neurotransmitter transporters, including DAT, SERT, NET which belong to the same family
(SCL6), and as well some members of the EAAT family [15, 56, 84, 85]. The involvement of
PKC is not limited to the phosphorylation of the target proteins, but it has been well
demonstrated that an intrinsic signaling cascade dependent on PKC also leads to ubiquitination
and depletion of the transporters from the plasma membrane. The main goal of this specific aim
was to determine if PKC promotes ubiquitination of GlyT1, which also belongs to the SCL6
family and shares a common topology with its other members. As shown in Fig.7, GlyT1
purified from PAE-C lysates shows a higher ubiquitination between 30-60 minutes incubation
with PMA an activator of conventional and novel PKCs. This effect is dependent on PKC since,
ubiquitination was prevented when prior to PMA stimulation the cells were treated with BIM a
general PKC inhibitor. It has also been reported that upon activation of PKCs, neurotransmitter
uptake can be significantly decreased [56, 64, 65, 75, 83, 85]. This reduction in activity is
attributed to internalization of the transporters. As observed in Fig.8, stimulation of the cells with
PMA dramatically decreases the availability of GlyT1 at the plasma membrane and internalized
transporter co- localizes with early endosomes (EEA1).
A well-known process called de-sensitization is employed by receptors to prevent overactivity under certain circumstances [86-88], and it has been characterized by the presence of the
internalized protein in structures known as recycling endosomes, which differ from late
endosomes whose ultimate destination is the lysosome. In contrast, recycling endosomes takes
back the internalized receptor to the plasma membrane. Surprisingly, for GlyT1 we could
observe co-localization with both recycling and late endosomes after 60 min incubation with
PMA (Fig.9), consistent with results that were previously observed on DAT [55]. By performing
a quantification on the number of recycling or late endosomes co- localizing with the transporter,
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our data indicates that approximately 90% of the recycling endosomes co- localized with GlyT1,
and about 40% of the late endosomes showed co-localization. These data suggest that GlyT1 can
be recycled back to the plasma membrane, but it can also be targeted to the lysosome for
degradation.
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Chapter 3: Mapping ubiquitination sites on the Glycine transporte r 1 (GlyT1)

Previous studies have been performed to study the specific residues located on membrane
transporters that are the target of post-translational modifications, such as phosphorylation and
ubiquitination. Techniques such as site-directed mutagenesis, has shown great success

in

determining the specific location of these residues [55, 58]. It has been previously demonstrated
that lysine residues present at the amino terminal of the dopamine transporter (DAT), which
belongs to the same family of neurotransmitter transporters and shares a similar topology with
GlyT1, are essential not only for ubiquitination of the transporter, but as well, for endocytosis
and protein stability of DAT. Studies performed on the glutamate transporter (GLT1) showed
evidence supporting that lysine residues present at both amino and carboxyl terminals are
essential for ubiquitination, and only by mutating all of them GLT1 ubiqutination is prevented.
Interestingly, only the lysine residues located at the carboxyl terminal seem to play a role on
internalization and protein stability of GLT-1. A recent study shows that the cluster of lysines
located at the C-terminal of GlyT2 is essential for the PKC-regulation of the protein, and is
suggested that ubiquitination of the transporter resides on the availability of lysine 791
exclusively [55, 57, 78]. We have demonstrated that GlyT1 is ubiquitinated in a time-dependent
fashion by PKC, and this aim is intended to determine the specific lysine residues that are a
target for this modification. In order to map the sites that are being modified by ubiquitin, we
performed mutations of the lysine residues present at both the amino and carboxyl terminals of
GlyT1b and GlyT1c into arginines (Fig.10). The objective of this aim is to identify the specific
residues essential for PKC-dependent ubiquitination of GlyT1b and GlyT1c stably expressed in
PAE-cells and assess its importance on the regulation of the transporter. The sub-aims are: i)
study which lysine residues in GlyT1 are modified by ubiquitin. ii) Determine the importance of
these residues on the internalization, phosphorylation and stability of GlyT1.
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3.1 Materials and Methods.

3.1.1 Chemicals and antibodies.

[3 H]-Glycine was purchased from Perkin Elmer Life Scientific (Boston, MA). Phorbol
12-myristate 13-acetate (PMA), N-ethylmaleimide, Filipin, Nystatin, anti-FLAG M2 affinity gel,
the GlyT1 inhibitor ALX 5407 and rabbit anti actin antibody were purchased from Sigma (St.
Louis Mo). Ni-NTA agarose was from Qiagen (Hilden, Germany). Monoclonal mouse P4D1 to
ubiquitin was from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal antibody to EEA.1
was purchased from BD transduction laboratories (San Jose, CA). Texas red lysotracker was
from Invitrogen (Carlsbad, CA). Fluorescently or HRP- labeled secondary antibodies were from
Jackson Immunoresearch Laboratories, Inc. (West Grove, PA). Rabbit polyclonal antibodies to
GlyT1 were kindly donated by Detlev Boison and Dietmar Benke (University of Zurich).
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3.1.2 Site-Directed Mutagenesis.

Single and multiple amino acid substitutions at the intracellular amino and carboxytermini were performed using FH-GlyT1B and FH-GlyT1C as templates and a QuickChange
site-directed mutagenesis according to the manufacturer’s protocol (Invitrogen). The mutations
were verified by automatic dideoxynucleotide sequencing. Transfection of PAE cells to create
stable cell lines with the mutated GlyT1 were performed as previous ly describe in section 2.1.2.

3.1.3 Phosphorylation assay, gel electrophoreseis and western blotting.

Cells expressing wt-GlyT1, NTK-GlyT1, CTK-GlyT1, and NTK-CTK-GlyT1 proteins
were grown in 35- mm dishes and treated with DMSO or PMA (1µM) for 30 min at 37˚C. Cells
were then incubated in a DMEM- phosphate free media supplemented with 5% dialyzed-FBS for
6 h, followed by the addition of 100-125 μCi of [32P]-orthophosphoric acid/ml. After 2 h
incubation, GlyT1 phosphorylation was stimulated with 1 μM PMA for 30 minutes and as a
negative control with DMSO for 30 min. After incubation, cells were washed twice with Ca2+and Mg2+-free cold phosphate-buffered saline (CMF-PBS) and lysed in a ice-cold-buffer
containing 25 mM HEPES, pH 8.0, 100 mM NaCl, 15 mM imidazole, 10% glycerol, 1% Triton
X-100, 1% sodium deoxycholate, 10 mM N-ethymaleimide, 10 mM sodium fluoride, 1X
phosphatase inhibitor cocktail, 1 mM sodium orthovanadate, 1 mM phenylmethanesulfonyl
fluoride and 10 μg/ml aprotinin and 10 μg/ml leupeptine. Lysates were cleared by centrifugation
at 14,000g and soluble GlyT1 was purified by a double affinity chromatography. Briefly, cleared
lysates were incubated with Ni-NTA affinity agarose beads for 1 hour and eluted with imidazole.
The eluted protein was incubated further with anti- flag affinity agarose beads for 4 h and eluted
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with 100 mM glycine, pH 3.5 [56]. The fractions containing GlyT1 were subjected to 8.0% SDSPAGE and transferred to a nitrocellulose membrane as previously described. Finally, the
nitrocellulose membranes containing
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P-GlyT1 were subjected to autoradiography followed by

Western blot using mouse and rabbit monoclonal antibodies to ubiquitin or GlyT1, respectively,
followed by secondary antibodies conjugated with horseradish peroxidase. Signal intensities
were quantitated with ImageJ (NIH).

3.1.4 Immunofluorescence and microscopy.

Cells expressing wt-GlyT1, NTK-GlyT1, CTK-GlyT1, and NTK-CTK-GlyT1 proteins
were grown in 35- mm dishes and treated with DMSO or PMA (1µM) for 30 min at 37˚C. After
treatment, the cells were washed with BSA-PBS, fixed with freshly prepared 4%
paraformaldehyde for 15 min at room temperature and mildly permeabilized using a 3- min
incubation in BSA-PBS containing 0.1% Triton X-100 and 0.5% BSA at room temperature. The
cells were then incubated at room temperature for 1 h with primary antibodies (1:500) diluted in
BSA-PBS and subsequently incubated for 1 h with secondary antibodies labeled with CY3 or
Alexa 488 (Jackson ImmunoResearch Laboratories). Both primary and secondary antibody
solutions were pre- cleared by centrifugation at 100,000 X g for 20 min. After staining, the
coverslips were mounted in Mowiol (Calbiochem). Results were monitored through fluorescent
microscopy.

3.1.5 Surface Biotinylation.

Cells expressing wt-GlyT1 and the NTK-CTK-GlyT1 mutant were grown in 35- mm
dishes and biotinylated as described previously [55, 89] .Briefly, the cells were washed with cold
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PBS containing 0.1 mM CaCl2 and 1 mM MgCl2 (PBS) and incubated for 20 min on ice with
1.5 mg/ml sulfo-N-hydroxysuccinimidobiotin (EZ-Link sulfo-NHS-biotin, Pierce) in PBS,
followed by a second incubation with fresh sulfo-NHS-biotin. After biotinylation, the cells were
washed twice with cold PBS, incubated on ice with 0.1 M glycine in PBS, and washed with PBS
again. The cells were then solubilized in lysis buffer supplemented with 10 mM Tris-HCl (pH
7.5) at 4°C. The lysates were cleared by centrifugation for 10 min and the biotinylated proteins
were precipitated with NeutrAvidin beads (Pierce), washed five times with lysis buffer (pH 8.0),
and denatured by heating the beads in sample buffer at 95°C for 5 min.
To precipitate nonbiotinylated proteins, supernatants from the NeutrAvidin precipitation were
further subjected to Ni-NTA affinity chromatography. The precipitates were washed five times
with lysis buffer, the protein was then eluted in lysis buffer containing 300 mM imidazole, and
denatured by heating in sample buffer. The NeutrAvidin beads and Ni-NTA precipitates were
subjected to SDS-PAGE and Western blotting with GlyT1 antibodies. Quantifica tions were
performed using densitometry and Image J software.

3.1.6 Glycine Uptake

Glycine uptake was performed as previously described with the following modifications[90].
Cells were grown to 90 - 100% confluence and washed three times with 0.25 ml of Hepes buffer
(10 mM Hepes pH 7.4, 135 mM NaCl, 2 mM KCl, 1 mM CaCl2 , 1 mM MgSO 4 and 10 mM
glucose). Glycine uptake was initiated by the addition of 0.25 ml Hepes buffer containing 4 µCi
of [3 H]-glycine/ml and a concentration of 400µM glycine. After 10 minutes at 37o C, the buffer
was removed and cells washed twice with ice-cold buffer following by extraction with 0.2 N of
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NaOH. Glycine uptake was determined by scintillation spectroscopy and specific glycine uptake
is defined as the difference between GlyT1- mediated glycine uptake and unspecific glycine
uptake measured simultaneously from parental cells transfected with pCDNA3.1. Protein
concentration was determined as described by Bradford [91].

3.1.7 Protein Degradation Assay.
Wild type GlyT1 and mutants expressed in PAE-C were grown to 90-100% confluence,
and then incubated for 2h with cycloheximide (50µg/ml) as described in Miranda et al., 2005,
preceded by treated with DMSO (6h) or 1µM PMA (2, 4, 6h) respectively. The cells were
washed three times and proteins were solubilized, as previously described. The cleared lysate
was quickly mixed with loading dye and heated. Total lysates were subjected to electrophoresis
and western blotting employing monoclonal rabbit antibodies to GlyT1 and α-actin, followed by
corresponding secondary antibodies conjugated with horseradish peroxidase, and detection using
the enhanced chemiluminescence kit from Pierce. Quantification was performed using
densitometry and Adobe Photoshop software.

3.2 Results.

3.2.1 Mutations of lysine sites at N- and C-termini abolish ubiquitination and endocytosis of
GlyT1.
For the dopamine transporter it was previously demonstrated that accelerated endocytosis
triggered by PKC activation was a result of enhanced DAT ubiquitination [92, 93].
Ubiquitination and phosphorylation of several transporters such as DAT, NET and SERT have
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been shown to involve residues at either N- or the C-termini. Furthermore, many proteins are
reported to interact with either tail of a transporter, probably to regulate the phosphorylated or
ubiquitinated state of the transporter. The N-termini of human GlyT1b contains two (K25 and
K31) or three (K45 unique to GlyT1c and K79, K85 the corresponding lysines in GlyT1b)
lysines. At the C-termini, GlyTs have three highly conserved lysines residues (GlyT1b: K577,
K581, K619; GlyT1c: K631, K635, K673, Fig.10). To analyze the role of lysine residues located
in the N- and/or the C-terminal tail in GlyT1 ubiquitination and given that ubiquitination sites
have been shown to be highly redundant in other plasma membrane transporters. A combination
of single and multiple lysines at the amino and/or carboxyl-termini were replaced with arginine
and stably expressed in PAE cells. Fluorescence microscopy analysis showed that lysine
mutations did not impair the trafficking since GlyT1 mutants were efficiently delivered to the
plasma membrane (Appendix Fig.2), and were not affected in endocytosis by PMA (Fig. 12).
These results suggest that no single lysine at either terminal tails is responsible for ubiquitination
and endocytosis.
We therefore expected that several lysine residues were able to function as ubiquitin acceptor
sites. To this end, we expressed GlyT1 mutants devoid of lysine residues at the amino and
carboxy-terminal tails and analyzed by western blotting. As shown in Fig.11, removal of lysine
residues at either amino (NTK) or carboxy (CTK)-terminal tails did not prevent ubiquitination
for all GlyT1 isoforms. The elimination of lysines at both tails (NTKCTK) abolished PKCdependent ubiquitination to levels similar to tho se obtained from GlyT1 purified from nonstimulated cells. Similar results were obtained with the mutations of the 5 lysine residues
available at both amino and carboxyl terminal of GlyT1 b isoform (Appendix Fig.3). Altogether,
these data suggest that all the lysines present at either N- or C- tail were able to conjugate with
ubiquitin moieties and may serve as acceptor sites.
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3.2.2 PKC-induced internalization and degradation of GlyT1 is impaired by lysine
mutations.
Previous studies have shown that replacement of lysine residues for arginines at the N-,
C- or both terminals prevent ubiquitination and internalization of DAT, GLT-1, and recently
GlyT2. It was also observed that the protein stability was increased by these mutations [55, 57,
77, 79]. As it can be observed in Fig.12A, cells expressing wt-GlyT1, NTK-GlyT1 and CTKGlyT1 were internalized and co-localized with early endosomes (EEA1), while the double
terminal mutation NTKCTK-GlyT1 shows similarity to the control treatment in which the
majority of the transporter remains at the plasma membrane. These results suggest the essential
role of ubiquitin on the endocytotic mechanism of GlyT1, confirming the reports that ubiquitin
serves as a signal for recruitment of endocytic machinery to its targets [31, 86]. To further
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confirm whether ubiquitination of GlyT1 is involved in PKC-induced internalization and GlyT1
cell-surface availability is not decreased when ubiquitination is inhibited, we performed a
biotinylation assay. After activation of PKC with PMA (30 min), a membrane impermeable
biotin reagent was utilized to covalently label and separate cell membrane proteins (biotinylated)
from intracellular proteins (non-biotinylated). As shown in Fig.12B, C, and D, the fractions of
biotinylated protein in non-stimulated cells are similar for wtGlyT1 and NTKCTK-GlyT1. By
contrast, PMA incubation of the wtGlyT1 caused a 25-40% reduction on the biotinylated protein
levels, while for NTKCTK-GlyT1 there was a no reduction on the surface-exposed transporter.
The decreased internalization of the double terminal mutant of GlyT1 (NTKCTK) and the
absence of co-localization with early endosomes (EEA1), even under the stimulation of the cells
with PMA as shown in Fig.12A, suggests there might be a greater protein stability. For this
purpose, we then proceed to test the role of these lysine substitutions in the degradation of the
transporter. GlyT1 expressing PAE cells were incubated with Cycloheximide for 2 hours to stop
protein synthesis, followed by PMA stimulation for 0h, 2h, 4h, and 6h. We detected that
expression of GlyT1 was decreased after 2h incubation with PMA in wt, NTK, and CTK, thus
shortening the half- life of the protein. The protein amount reduction continued gradually as the
PMA incubation time increased (Fig.13). In contrast, NTKCTK mutant maintained constant
protein levels throughout the incubation time intervals. All these evidence taken together,
strongly suggests that ubiquitination of GlyT1 is an essential mechanism for internalization of
the transporter. In addition, it plays a pivotal role on PKC-dependent acceleration of GlyT1
degradation.
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3.2.3 The effects of GlyT1 ubiquitination on phosphorylation and kinetics of the
transporter.
Our group previously demonstrated that GlyT1 is phosphorylated in response to PKC
activation, and that transport capacity was reduced as a consequence of PMA stimulation [59].
To analyze if ubiquitination of the transporter has any effect on other posttranslational
modifications, we assessed the importance of the lysine substitutions on phosphorylation of
GlyT1. The wt and mutants, NTK, CTK and NTKCTK GlyT1 expressed in PAE cells were
incubated with PMA for 1h; they were then lysed and purified as previously described, followed
by SDS-PAGE and analyzed by autoradiography. Lysine replacement to arginines did not affect
phosphorylation of the transporter and the three mutant cell lines showed similar phosphorylation
levels as the wt (Fig.14A). PKC is known to phosphorylate its targets at serines and threonines
[94, 95], and these potential phosphorylation sites were kept intact in the constructs with lysine
mutants performed to GlyT1. This can explain the persisting phosphorylation of the transporter
even in the absence of lysine residues at the N- and C- terminal. It is important to state that
although phosphorylation is taking place in GlyT1 independently of ubiquitination, the effects of
preventing GlyT1 phosphorylation on ubiquitination have not been investigated. Recent studies
have shown that mutating serine residues has no effects on the PKC dependent down-regulation
of DAT and GLT-1. This suggests that ubiquitination still takes place and regulates these two
transporters [75, 76].
GlyT’s main role is the clearance of glycine from the extra-cellular space. This is the
proposed mechanism through which glycine concentrations present at the synapse are tightly
regulated by this protein [96]. It has been previously postulated that internalization of GlyT1 is
the main mechanism to cause a decrease in glycine transport. To examine the relationship
between decreased availability of GlyT1 at the plasma membrane and its effects on glycine
uptake, we performed a glycine uptake assay to study the effects of lysine substitution on
transport. WT-GlyT1, NTK and CTK mutants exhibit a decrease between 40-60% on glycine
transport upon treatment with PMA (30min), while the NTKCTK mutant under the same
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conditions only experienced a non-significant 5-7% decrease on Glycine uptake (Fig.14B). All
these data together shows the pivotal role of PKC-dependent ubiquitination on cell-surface
expression and activity (Glycine transport) of GlyT1.
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3.3 Discussion.
Ubiquitination is a highly regulated process that is important for many cellular functions,
including endocytic trafficking of membrane proteins and targeting of cytosolic proteins for
degradation by the proteasome [31]. Ubiquitination has been implicated in endocytosis and
lysosomal targeting of various transmembrane proteins such as tyrosine kinases, G-protein–
coupled receptors, epithelium sodium channels, and several neurotransmitter tranporters [56, 64,
75, 85, 97-100]. In the present study, the essential role of ubiquitin on the endocytosis and
stability of GlyT1 is demonstrated. The approach to map GlyT1 ubiquitination sites consisted on
creating single and multiple lysine mutants at N- and C- termini of the transporters. As observed
in Fig. 12 and Appendix Fig.2, mutants were fully functional in proper localization and glycine
uptake.
In Fernandez-Sanchez et al [101], it was stated that Lys 619 present at the C-terminus of
GlyT1b was essential for ubiquitination and depletion of this lysine abolished both ubiquitination
and internalization of the transporter. Our results showed that ubiquitin can modify any of the 6
lysine residues present at either the amino or carboxyl terminal on the c isoform of the
transporter. It is similar for the b isoform, in which only by substitution of the 5 lysine residues
present at both terminals ubiquitination was abolished (Appendix Fig.3). Literature has
suggested the importance of PKC activation on the reduced transport capacity (Vmax) of
numerous trans- membrane transporters, but with a slight or no change at all in Km [59, 65, 68].
Suggesting that this decrease in activity might be a consequence of a reduced availability on the
cell-surface protein. Immunofluorescence studies confirmed that by inhibiting ubiquitination
(Fig. 11) it prevents internalization of the transporter (Fig.12), there is an increases on protein
stability (Fig. 13), and re-establishment of glycine uptake to basal levels (Fig. 14 B). All these
data suggests that ubiquitin might be acting as a mediator to recruit the endocytotic machinery.
Our results also show that mutations of lysines at both terminals of the transporter did not
prevent phosphorylation of GlyT1 (Fig. 14A), which has been also confirmed to be a PKCdependent modification [59], but it is clearly not dependent on ubiquitination. The exact
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mechanism by which PKC promotes ubiquitination of GlyT1, and whether it is a direct or
indirect signaling from the kinase stills need to be investigated.
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Chapter 4: Identification of the specific PKC isoform and E3 ligase involved on the
ubiquitination of the Glycine transporter 1 (GlyT1).
It has been suggested that PKC-dependent posttranslational modifications regulate
various members of the SCL6 family of neurotransmitter transporters [23, 56, 65, 68-71, 102].
Our group previously reported PKC-dependent phosphorylation and downregulation of
GlyT1[59]. The dopamine transporter (DAT) has been used as a model protein for the study of
PKC regulation of neurotransmitter transporters. Several studies demonstrate that PKC
downregulation of DAT is evidenced in a decrease of DA uptake and redistribution of the protein
from the plasma membrane [23, 55, 56]. It has also been reported that DAT and PKCβ form a
complex in rat striatal slices, and is suggested that this isoform is responsible for mediating DAT
phosphorylation [59, 76]. We have observed that inhibition of PKC β with the selective
inhibitors: β inhibitor and LY333531 prevented phosphorylation of GlyT1. The down-regulating
effect of PKC activation with PMA on glycine uptake was reversed upon inhibition of both
PKCα and β, with the potent inhibitor Gö6976. In the present study the main goal was to
determine which PKC isoform is implicated in ubiquitination and internalization of GlyT1. Since
it has been previously demonstrated that ubiquitination and phosphorylation of GlyT1 are two
independent post-translational modifications orchestrated by PKC, but phosphorylation is occurs
independently of GlyT1ubiquitination. Two different approaches were used: i) pharmacological
analysis that consisted in employing PKC-isoform specific inhibitors and ii) using an siRNA
smart pool targeting PKC α and β. We could observed that the presence of PKCα is essential for
ubiquitination and internalization of the transporter.
A great number of neurotransmitter transporters and ion gated channels have been shown
to be down-regulated by the action of different kinases. The main mechanism postulated as
responsible for this down-regulation is ubiquitination, which is a known signal of endocytosis [3,
34, 37, 61, 63, 64, 72, 103, 104].

The precise mechanism that promotes ubiquitination in

response to kinase activation has been under study for the past years, and it has been observed
that activation of distinct kinases might induce a switch in the activity of E3- ligases upon
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phosphorylation. E3 ligases play an important role as the last step of the ubiquitin conjugation
multi-step and due to the large amount of E3 ligases it is believed they are responsible for target
specificity [61, 62]. The Nedd4 family is a widely expressed ubiquitin- E3 ligase in the brain. It
has been shown that PKC-dependent ubiquitination of the dopamine transporter (DAT) [93,
105], cationic aminoacid transporter (CAT-1) [106], excitatory amino acid transporter 1 and 2
(EAAT1 and EAAT2) are dependent on Nedd4 ligases [106]. Taking advantage of a smart pool
siRNA targeting of Nedd4-1 and Nedd4-2 we also wanted to determine whether PKC-dependent
ubiquitination of GlyT1 is dependent on either of these ligases.

4.1 Materials and Methods.
4.1.1 Materials
Phorbol 12- myristate 13-acetate (PMA), N-ethylmaleimide,

and rabbit anti-actin

antibody were purchased from Sigma (St. Louis Mo). Ni-NTA agarose was from Qiagen
(Hilden, Germany). On-target smart pools siRNA against PKCα, PKCβ, Nedd4-1 and Nedd4-2
were purchased from Dharmacon. Bisindolylmaleimide I (BIM), HDBBE (2,2’,3,3,4,4′Hexahydroxy-1,1′-biphenyl-6,6′-dimethanol dimethyl ether),

rottlerin,

Gö6976, Gö6983,

LY333531 and PKCβ inhibitor (3-(1-(3-Imidazol-1-ylpropyl)-1H- indol-3-yl)-4-anilino-1Hpyrrole-2,5-dione) were from EMD Biochemicals (San Diego, CA). Monoclonal mouse P4D1
ubiquitin antibody, monoclonal mouse PKC α and PKC β antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA). Monoclonal antibody to EEA.1 was purchased from BD
transduction laboratories (San Jose, CA). Texas red lysotracker was from Invitrogen (Carlsbad,
CA). Fluorescently or HRP-labeled secondary antibodies were from Jackson Immunoresearch
Laboratories, Inc. (West Grove, PA). Rabbit polyclonal antibodies to GlyT1 were kindly donated
by Detlev Boison and Dietmar Benke (University of Zurich). YFP-PKCβII and YFP-PKCβI
constructs were kindly donated by Haley E. Melikian (UMASS medical school).
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4.1.2 Cell culture and transfections.
Cell culture and transfection of PAE cells with YFP-PKCβII and YFP-PKCβI were
perfomed as described in section 2.1.4. SiRNA transfections were performed as described by the
manufacturer (Dharmacon, Inc. Lafayette, Co). Affinity chromatography, western blotting,
immunostaining, and microscopy techniques are described in previous sections.

* IC50 values for the different PKC isoforms of the inhibitors tested on this study are
expressed in μM. [22, 107, 108]
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4.2 Results.
4.2.1 PKC α/β inhibitor Gö6976 prevents GlyT1 ubiquitination and internalization.
Glutamate transporter EAAC1 cell-surface expression is regulated by PKC α, while its
catalytic activity is regulated by the PKC ε isoform [60], suggesting that different PKC isoforms
might be regulating directly or through a signaling cascade different post-translational
modifications. Our group previously reported PKCβ- dependent phosphorylation of GlyT1 [59];
PKCβ selective inhibitors β- inhibitor and LY333531 prevented phosphorylation of the
transporter. The effect of PKC activation with PMA on glycine uptake by GlyT1 was reversed
upon inhibition of both PKC isoforms α and β with the potent Gö6976 inhibitor [107]. Previous
sections of this dissertation have shown that phosphorylation of GlyT1 is independent from
ubiquitination, and that the latter is more tightly related to endocytosis of the transporter. To
determine the PKC isoform involved in GlyT1 ubiquitination and its decrease of cell-surface
expression, we used PKC inhibitors targeted to its different isoforms.
PAE cells stably expressing FH-GlyT1b were treated with concentrations between 50100 fold above the IC 50 value as shown in Table 2, followed by PMA (1µM) treatment. As
shown in Fig.15, PMA treatment significantly increased GlyT1 ubiquitination. This action is
prevented by previous treatment with 1µM BIM (general PKC inhibitor), 1µM Gö6983
(conventional PKCs inhibitor), and 1µM Gö6976 (PKCα/β). The presence of both PKC isoforms
(α and β) in PAE-C has been documented in a previous article from our group [59]. Meanwhile,
prior treatment with PKCβ inhibitor (200nM) and the novel PKC inhibitor Rottlerin (10µM)
followed by PMA (1µM), did not prevent ubiquitination of the transporter.
To study the effects of these PKC specific inhibitors on the cell- surface expression of the
transporter we performed immunofluoresence assays utilizing the PKC isoform specificinhibitors and PMA at the same concentrations as for the ubiquitination assay. Our findings
agreed once again with the observation that ubiquitination is essential for the endocytosis of
GlyT1. Only those inhibitors that were unable to prevent ubiquitination did not have any effect
on the internalization of the transporter (Fig.16). Gö6976, an inhibitor of conventional isoforms
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PKCα and β, prevents ubiquitination and internalization of the transporter, while β- inhibitor does
not exert any effects. These results suggest that PKCα is the most viable isoform to be
responsible for ubiquitination and internalization of GlyT1.
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4.2.2 siRNA specific for PKCα and PKCβ
Although distinct PKC isoforms differ in tissue distribution and signaling pathways
regulation, they share structure similarities [24, 94]. Conventional PKCs α and β have great
structural resemblance and a close molecular weight; 80kDa for PKCα and 79kDa for PKCβ.
This resemblance complicates the exact identification of these isoforms by western blotting.
Because of the absence of a specific PKC α inhibitor, we needed a more reliable method to
discriminate between α and β. For this purpose, we employed siRNA targeting PKCα and PKC
β. To probe the specificity of the siRNAs, we transfected PAE-C with a construct that contains
PKCβ tagged with YFP as a reporter to differentiate among the molecular weights of the
isoforms. This allowed us to identify the efficacy of both siRNAs employing microscopy and
western blot, by taking advantage of the shift in the molecular weight of the YFP-PKCβ. The
YFP-PKCβ construct has a molecular weight of approximately 110kDa. As shown in Fig.17A,
siRNA directed against PKCα has no effect on the expression of YFP-PKCβ. For the western
blot analyses, three antibodies directed against PKCβ isoform from different companies (Santa
Cruz, abcam, and BD Biosciences) were used as probes. All the antibodies recognized a band at
79kDa (PKCβ molecular weight) even after siRNA transfection (Data not shown). To prove the
efficiency of the siRNA targeting PKCβ we used PAE-C expressing YFP-PKCβ. The 110kDa
band was not detected upon treatment with PKCβ siRNA, in contrast it was detected on the
Mock and non-target siRNA treated-samples (Fig. 17 B). These results suggest that
commercially available antibodies directed against PKCβ, might be recognizing other PKC’s
isoforms. There have been 9 distinct isoforms of PKC identified which range between 76-81 kDa
[109, 110]. All these data together, suggests that siRNAs employed in this study are specific for
either α or β isoforms of PKC.
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4.2.3 Silencing PKCα prevents PMA-activated PKC effects on GlyT1.
The pharmacological analysis strongly suggested PKC α is the main isoform responsible
for the regulation of GlyT1 in PAE-C. Since GÖ6976 a specific PKCα and β inhibitor, abolished
the PMA effects on the transporter, while the β inhibitor did not show any inhibitory effect on
ubiquitination and internalization of GlyT1. However, the absence of a strong PKC α inhibitor
did not allow us to demonstrate that inactivation of PKCα is preventing ubiquitination and
internalization. To investigate the role of PKCα, we employed a siRNA smart pool against
PRKCA gene. RNA interference revealed the importance of PKCα isoform; as shown in
Fig.18A, ubiquitination and endocytosis (Fig.19) are prevented upon PKCα inhibition. As a
control and to confirm our pharmacological analysis results, we also performed silencing of PKC
β that confirmed that ubiquitination (Fig.18 B) and internalization (Fig.19) are not dependent on
the β isoform. Due to the absence of a commercially available antibody that is specifically
directed towards the β isoform of PKC, we had to use YFP-PKC β constructs as a control to
show the efficacy of the siRNA in silencing the β isoform (Fig.18).
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4.2.4 Nedd4-1 and Nedd4-2 are not involved on GlyT1 ubiquitination.
The numerous transporters and receptors that have been reported to be ubiquitinated by
Nedd4 family, strongly suggests this HECT E3- ligase as a potential candidate to mediate
ubiquitination of GlyT1 [3, 34, 37, 61, 63, 64, 72, 103]. It has been described for two
neurotransmitter transporters (DAT and EAAT2), in which the presence Nedd4-2 is essential for
ubiquitination [61, 63]. Also reported, Nedd4-1 another member of this ligase family to mediate
the ubiquitination of CAT-1 [106]. Stable expressing FH-GlyT1b PAE cells, were transfected
with a smart pool targeting Nedd4-1, Nedd4-2 and Nedd4-1/4-2. Followed by treatment for 30
min with vehicle (DMSO) or PMA (1 µM), total cell lysates and FH-GlyT1 purified samples
were separated by SDS-PAGE and subsequently blotted against ubiquitin, Nedd4-1, Nedd4-2,
GlyT1, and actin antibodies. As our results show (Fig.20), we were unable to detect a change or
decrease in ubiquitination of GlyT1 on cells transfected with any of the siRNAs directed towards
the Nedd4 ligases. To investigate the effect of silencing Nedd4-1 and Nedd4-2 on the
internalization of the transporter, we performed an endocytosis assay following the protocol
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previously described. As shown in Fig.21, silencing of Nedd4-1, Nedd4-2 and Nedd4-1/4-2 did
not exert any effect in preventing internalization of GlyT1. Once again confirming that these E3
ligases are not mediating ubiquitination and endocytosis of the transporter.
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4.3 Discussion
The involvement of PKC as a regulator of several neurotransmitter transporters, and other
plasma membrane proteins has been addressed on numerous occasions [23, 56, 65, 68-71, 94,
111]. Several studies have postulated that there is a differential PKC cell- and organelle-specific
expression. It is believed that this accounts for the involvement in different signaling pathways
between PKC isoforms [21, 109, 112]. It was previously reported that glutamate transporter
EAAC1 cell-surface expression is regulated by PKCα, while its catalytic activity is regulated by
the ε isoform [60]. DAT has shown to associate with PKC β in striatal slices, and when it is
expressed in PAE cells it is phosphorylated by the PKC β isoform [59, 76]. Morioka et al., [69]
showed that down-regulation of GlyT1 in C6 cells was prevented by the potent GÖ6976 inhibitor
[107]. They also reported that PKC β was not expressed on C6 cells, and therefore concluded
that PKC α was indeed responsible for the glycine uptake down-regulation suffered by GlyT1
upon PKC activation. Our group previously reported PKCβ- dependent phosphorylation of
GlyT1 in PAE cells, and showed the expression of PKCα and β in PAE and C6 cells, differing
from those results reported by Morioka et al., [59]. Specific inhibitors for PKCβ, such as βinhibitor and LY333531 prevented phosphorylation of the transporter. The effect of PKC
activation with PMA on glycine uptake by GlyT1 was reversed upon inhibition of both PKC
isoforms α and β. In the present study our main goal was to determine the PKC isoform involved
in ubiquitination and internalization of GlyT1. Because ubiquitination and phosphorylation are
both orchestrated by PKC, but they are not dependent on each other, we therefore hypothesized
they might be regulated by different PKC isoforms. Our results show that Gö6983, an inhibitor
of conventional PKCs, and Gö6976 a PKCα and β inhibitor, were effective in preventing both
ubiquitination and internalization of GlyT1. In contrast, β-inhibitor specific for PKC β and
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rottlerin an inhibitor of novel PKCs did not have any effect on GlyT1 (Figs.15 and 16). The
absence of an effective and specific PKC α inhibitor did not allowed us to further characterize
the role of this isoform in ubiquitination and internalization of GlyT1. As a second approach to
confirm our preliminary results, we used siRNA directed against PKCα and β. To confirm the
specificity of the siRNA we transfected PAE cells with PKCβ tagged to YFP as a reporter. We
showed in Fig.17 via western blot and immunofluorescence analysis that the siRNAs are specific
to the isoforms alpha or beta. By analyzing the effects of silencing PKCα and β respectively, we
could conclude that the presence of PKCα is essential for ubiquitination and internalization of
the transporter (Figs.18 and 19).
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The specificity of ubiquitination is dictated by the last step of this proce ss, in which the
E3 ligase finalizes the transfer of ubiquitin to its target. It has been reported that the Nedd4
family plays a pivotal role in ubiquitination of several neurotransmitter transporters and receptors
[34, 37, 63, 64, 103, 104]. Sorkina et al., [63] reported that ubiquitination of DAT was dependent
on Nedd4-2, consistent with previous evidence that highlights the importance of ubiquitination
on transporter internalization [55, 56]. Depletion of Nedd4-2 also impaired internalization of the
dopamine transporter. It has been also reported that Nedd4-1 another member of this ligases
family mediates the ubiquitination of CAT-1 [106], which is also ubiquitinated and internalized
in a PKC-dependent fashion. The silencing of Nedd4-1, Nedd4-2, and a combination of siRNA
for Nedd4-1 and Nedd4-2 together did not show any significant effect on the ubiquitination and
internalization of the transporter in PAE cells (Figs.20 and 21), suggesting that these ligases do
not participate in PKC-dependent ubiquitination of GlyT1.
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Chapter 5: Overall Discussion and Concluding Remarks

The implications of NMDARs in the processes of learning and memory, its
association with the plasticity that promotes addictive effects of drugs, and the observation that
its dysfunction is related to several neurological diseases [44], have increased the interest on
discovering possible molecular targets that can modulate the actions of this receptor. Over the
last years, however, there has been an increased interest in identifying the role of NMDA
receptors in schizophrenia, making it a new target for drug discovery [8]. NMDA-R function
theory of schizophrenia proposes that impairment in NMDA-R function is associated with the
pathophysiology of schizophrenia, and suggests that enhancement of the receptor function may
produce efficacy for the treatment of schizophrenia. Consistent with this theory, clinical trials
throughout the last decade have demonstrated that the enhancement of NMDA-R function by
potentiating the glycine site of the receptor is efficacious in the treatment of schizophrenia and
other neurological pathologies in which an increased NMDARs activity might be beneficial,
such as OCD and Alzheimer’s [8, 12, 17, 18, 42].
Glycine concentration in glutamatergic synapses is regulated by GlyT1, which has been
postulated to have an important role in the regulation of this receptor. Enhancing NMDA-R
activity by increasing glycine levels via GlyT1 inhibition has been demonstrated and is being
pursued as an approach for the treatment of schizophrenia and OCD [42, 43, 113-115].
Recently, homozygote knockout GlyT1- mice were generated; alterations observed in these mice
had fatal consequences. Newborn GlyT1 knockout mice die the day of their birth and during the
short period of survival displayed severe motor and sensory deficits, which extended to the
respiratory system in which rhythmic breathing was severely depressed due to the glycinergic
over- inhibition caused by the sustained activation of glycine receptors (GlyRs) in the presence of
high levels of extracellular glycine [16, 96]. The importance of GlyT1 resides not only in the
crucial role it plays in regulation of excitatory synapses, but as well in inhibitory synapses. This
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is why we believe that getting further insight into the regulatory pathway of this protein is both
relevant and significant within the field of neurobiology, and drug development.
The main goal of this present work was to determine the regulation mechanism of GlyT1
exerted by PKC-dependent ubiquitination. We demonstrate the relationship between activation
of PKC and the regulation of GlyT1, following a similar mechanism to other members of the
Na+/Cl- coupled neurotransmitter transporters family [23, 56, 65-71]. It was previously
demonstrated that GlyT1 is phosphorylated by PKC, but here we show that ubiquitination of the
transporter is also dependent on PKC activation. Ubiquitin has been extensively identified as a
signal for internalization of its target proteins, this investigation presents evidence, which
demonstrates that endocytosis of GlyT1, is dependent on ubiquitination. Ubiquitination of GlyT1
promotes its internalization and co- localization with early endosomes, our results show that once
the transporter is internalized it can follow these two pathways; recycling that will eventually relocate the transporter back at the plasma membrane and degradation pathway in which the
transporter will be transferred to the lysosome for degradation. The exact mechanism of sorting
between recycling and late endosomes for GlyT1 is unknown, but it has been postulated that
after internalization deubiquitinases might play a role in recycling of proteins [35].
Understanding the exact mechanism through which GlyT1 is sorted between these two pathways
will be very useful to gain further knowledge on the role ubiquitin plays in the regulation of
GlyT1.
Ubiquitin can modify its targets by mono-ubiquitylation or forming poly-ubiquitin
chains attached to a lysine residue, the most common type of chains are Lys63 and Lys48 which
are known to follow different pathways Lys48 is specific for proteosomal degradation, while
Lys63 and mono- ubiquitylation are implicated in endocytic trafficking, signal transduction and
other cellular processes [31]. The use of site-directed mutagenesis has been a strategy emplo yed
to determine the location of this modification within target proteins, several plasma membrane
transporters have shown to be modified by ubiquitin at either the N-, C- or both terminal
ends[55, 57, 79]. Our results show that GlyT1 can be modified by ubiquitin at any of the 6
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available lysine residues present at either the amino or carboxyl isoform for the GlyT1c isoform
or the 5 lysine residues on GlyT1b. Suggesting that this modification is non-specific to a single
lysine residue, differing to what other groups have reported [101]. Mutation of all 5 or 6 lysine
residues (NTKCTK) prevents ubiquitination and we observed that only by abolishing
ubiquitination of GlyT1 the transporter remains at the plasma membrane. Our data strongly
suggest that ubiquitin acts as a recruiting signal for the endocytic machinery implicated on the
internalization of GlyT1. The ubiquitination of GlyT1 increases protein stability since the
transporter doesn’t get degraded at the same rate as the wt, NTK and CTK constructs, consistent
with our report that once internalized the ubiquitinated transporter co-localizes with late
endosomes which will eventually target GlyT1 for lysosomal degradation. Interestingly, it was
also observed that by abolishing ubiquitination of GlyT1 it exerts an inhibitory effect on the
PMA down-regulation of glycine uptake, even when the transporter still undergoes PKCdependent phosphorylation. This evidence elucidates the fact that although phosphorylation and
ubiquitination of GlyT1 are both mediated by PKC activation, phosphorylation dos not depend
on the capability of GlyT1 to get ubiquitinated. Several lines of investigation on neurotransmitter
transporters have pointed out a down-regulation of neurotransmitter uptake as PKC-dependent,
but this is the first report that shows this effect depends exclusively on PKC-dependent
ubiquitination of GlyT1 [65, 69, 83, 85]. All these data together, suggests that ubiquitination is
an important regulatory mechanism that modulates the distribution of GlyT1at the plasma
membrane, and given that GlyT1 is functional at the plasma membrane; therefore, ubiquitination
regulates its activity.
It was previously demonstrated that GlyT1 phosphorylation is mediated by PKCβ, but
glycine uptake down-regulation is reversed only by the inhibition of PKC α and β together [59].
Several studies have reported that more than one PKC isoform can mediate different signaling
pathways affecting the same target. This is the case of the glutamate transporter in which
activation of PKCα increases EAAC1 cell-surface expression, while activation of PKCε
increases the transporter activity independently of cell-surface expression [60]. For STAT3 it has
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been reported that both PKCε and PKCδ mediate its phosphorylatio n through different pathways
at different residues, but both pathways serve a common function which is to induce
cardioprotective effects [116]. These data strongly suggest that one protein can be modulated
through different pathways by different PKC isoforms, our aim was to investigate whether
phosphorylation, ubiquitination and internalization of GlyT1 are depe ndent on different PKC
isoforms. With the previous knowledge that although ubiquitination and phosphorylation of
GlyT1 are both promoted by PKC they do not seem to be dependent from each other as it is
shown in Fig.14A. To investigate the PKC isoform that mediates ubiquitination and
internalization of GlyT1 two different approaches were used; the first one was to employ specific
inhibitors targeting the different PKC isoforms, which showed that inhibition of PKCα and
PKCβ together prevented ubiquitination and internalization of GlyT1. The second approach was
to use siRNAs targeting PKCα and PKCβ, Our results clearly support the hypothesis that PKCβ
has no effect on the process of ubiquitination and internalization of GlyT1. It is PKCα alone, the
isoform that mediates ubiquitination and endocytosis of the transporter. This is consistent with
the previous results in which the down-regulation in glycine transport can only be reversed by
inhibition of both PKCα and β together. Because these transport assays were performed without
an effective PKCα inhibitor; therefore we cannot rule out the possibility that down-regulation in
glycine transport is promoted exclusively by PKCα activation. Our study has previously shown
that phosphorylation is not dependent on ubiquitination of GlyT1, when mutating the 6 lysine
residues at the N- and C- terminals abolished ubiquitination but it was observed that this didn’t
exert an inhibitory effect on phosphorylation of the transporter (Fig. 14A). It has been suggested
that phosphorylation can positively regulate ubiquitination by creating binding sites for E3ligases on target proteins [117], this is not the case of GlyT since abolishment of phosphorylation
by inhibiting PKCβ did not prevent ubiquitination.
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The exact mechanism through which PKC promotes the ubiquitination of GlyT1 still
needs to be investigated, but it is hypothesized that has to be part of a signaling cascade in which
the actions of the kinase promotes the interaction of GlyT1 with the ubiquitin machinery. The
last step of the ubiquitination pathway in which an E3 ligase participates, has been postulated to
provide specificity for target recognition due to the high number (over 600) of E3 ligases that
have been identified [31, 117]. Previous reports, have strongly suggested the action of the
ubiquitin E3- ligases in mediated PKC-dependent ubiquitination of other membrane proteins,
including neurotransmitter transporters in which 2 members of the NEDD4 family of ligases
have been found to be implicated in ubiquitination of other neurotransmitter transporters that
show high similarities with GlyT1[61, 63, 75, 103, 106]. Our results in which a smart pool
siRNA was directed towards Nedd4-1, Nedd4-2, and Nedd4-1/4-2 showed no influence in
preventing the ubiquitination of GlyT1.

In order to determine the signaling cascade that

regulates GlyT1 it is required to identify the E3 ligase; whether GlyT1 ubiquitination is a HECT
E3 ligase-dependent directly interacting with the transporter, or a RING E3 ligase acting as a
bridge between the E2 ligase and GlyT1 for the transfer of ubiquitin. The exact identification of
the E3 ligase can provide further knowledge in understanding the actions of PKC on this last step
conferring ubiquitin to GlyT1; the questions that still need to be answered are if the E3 ligase is
directly phosphorylated by PKC or if PKC activation might promote a signaling cascade through
the activation of other kinases or phosphatases that leads to the activation of the E3 ligase
targeting ubiquitin to GlyT1?
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Our study brought into perspective a molecular mechanism that can be implicated in the
regulation of neurotransmission in areas of the CNS system where GlyT1 acts as a modulator of
NMDARs. Our study model shows a mechanism (Fig.22) in which PKCα activation leads to a
signaling cascade or direct activation via phosphorylation of an E3 ligase that promotes GlyT1
ubiquitination. Ubiquitin attached to GlyT1 serves as a recruiting signal for endocytic machinery
that leads to internalization of the transporter, which can be recycled back to the plasma
membrane or targeted to the lysosome for degradation. Ubiquitin can modify any lysine residue
present at either the N- or C- terminal of the transporter, and regulates the activity of the
transporter by modifying GlyT1 concentration at the plasma membrane. This study provides
evidence to postulate PKC-ubiquitination as the main mechanism regulating the concentration of
GlyT1 at the plasma membrane, it is important to highlight that preventing phosphorylation of
the transporter by inhibition of PKCβ does not affect ubiquitination, which confirms that these
two modifications are independent from each other. Overall this study elucidates a mechanism
that decreases the density of GlyT1 in a PKC-dependent ubiquitination fashion and through the
effect it has on the expression of cell- surface GlyT1 it regulates its activity.
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